Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSCO neoadjuvant chemotherapy biomarker trial in operable breast cancer
2013-004307-39Phase 3Unknown
- Sponsor
- University of Birmingham
- Start
- Jan 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, epirubicin, cyclophosphamide, docetaxel and trastuzumab in breast cancer (2 arms), sponsored by University of Birmingham. Primary endpoint: Complete pathological response rate. Status: unknown.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-004307-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004307-39.